Healthcare tech firm Medtronic beats Q2 revenue estimates, raises guidance

Medtronic

18/11/2025 11:55

Overview

Medtronic fiscal Q2 revenue grows 6.6%, beating analyst expectations

Adjusted EPS for fiscal Q2 beats consensus, increasing by 8%

Company raises FY26 guidance for revenue growth and adjusted EPS

Outlook

Medtronic raises FY26 organic revenue growth guidance to 5.5%

Company increases FY26 adjusted EPS guidance to $5.62-$5.66

Company sees revenue growth acceleration driven by key programs

Result Drivers

CARDIAC ABLATION GROWTH - Revenue increased 71% driven by pulsed field ablation portfolio, with 128% growth in the U.S.

FAVORABLE COVERAGE - Received favorable coverage policies for Symplicity procedure for hypertension, addressing 18 mln people in the U.S.

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$9 bln
$8.87 bln (26 Analysts)
Q2 Adjusted EPS
Beat
$1.36
$1.31 (26 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy", 16 "hold" and 2 "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Medtronic PLC is $100.50, about 4.2% above its November 17 closing price of $96.28

The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 16 three months ago

Press Release: ID:nPnbZxX6La

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)